[Some specifics of tamoxifen's effect on the endometrium in menopausal cancer patients].
The study has been concerned with evaluation of tamoxifen effect in menopause, the nature of hyperplastic developments taking place in the course of that therapy as well as risk of endometrial carcinoma. Out of 276 breast cancer patients, 135 received tamoxifen whereas the rest were in control. Therapy was found to cause hyperplasia of the basal endometrial stroma. That in turn was followed by such benign changes as endometrial polyp formation. They were represented by an enlarged middle M-echo in ultrasound examination. No enhanced risk of endometrial carcinoma was reported.
Ashtrafian
L A
LA
Antonova
I B
IB
Chazova
N L
NL
Motskobili
T A
TA
Babaeva
N A
NA
Al'ditskiĭ
I A
IA
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000517:prevention & control; D004714:Endometrial Hyperplasia / Q000139:chemically induced*; D004717:Endometrium / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology; D020847:Estrogen Receptor Modulators / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011127:Polyps / Q000139:chemically induced; D017698:Postmenopause; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects*; D014463:Ultrasonography
D018931:Antineoplastic Agents, Hormonal; D020847:Estrogen Receptor Modulators; D013629:Tamoxifen